Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | CD4+ T-cell reconstitution in allo-HSCT settings

Jaap Jan Boelens • 24 Aug 2020
EBMT 2020
General

Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the use of early CD4+ T-cell reconstitution as a predictor of outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jaap Jan Boelens

4:54
Predicting immune reconstitution following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:20
Second cord blood transplant for patients who relapse following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
4:53
The influence of the pulmonary microbiome on outcomes after alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:23
PARACHUTE trial: ATG in HCST
Jaap Jan Boelens • 1 Sep 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals